ERBB2 and triple-negative breast carcinoma: pCR was reported in 23 (52.3%) HER2+/HR+ patients, in 23 (74.2%) HER2+/HR-negative patients, in 11 (17.2%) HER2-negative/HR+ patients and in 11 (37.9%) triple negative breast cancer patients.